Biosante Pharm (BPAX) Cash Flow Statement

Click line-items for a historical chart and %

Net loss
Depreciation and amortization	16.53M
Loss on disposal of fixed assets
Employee & director stock-based compensation	4.69M
Stock warrant expense - noncash
Convertible note fair value adjustment
Prepaid expenses, deposits and other assets
Accounts payable and accrued liabilities
Net cash (used in) operating activities
Purchase of fixed assets	-3.18M
Net cash (used in) investing activities
Proceeds from common stock option exercises	1.36M
Proceeds from issuance of common stock by registered direct offerings
Net cash provided by financing activities
NET (DECREASE) INCREASE CASH AND CASH EQUIVALENTS	-138.53M
CASH AND CASH EQUIVALENTS AT BEGINNING OF PERIOD	154.68M
CASH AND CASH EQUIVALENTS AT END OF PERIOD	16.16M
Interest paid	2.16M
Purchase of fixed assets on account, non-cash investing activity	102K

Entities mentioned with BPAX

View All Entities